Recent Advances in Dialysis Therapy in Japan

Editor(s): Nakamoto, Hidetomo (Saitama)
Nitta, Kosaku (Tokyo)
Tsuchiya, Ken (Tokyo)
Okada, Hirokazu (Saitama)
Hasegawa, Hajime (Saitama)

Chapter 1: New Opinions on Dialysis Therapy

Magnesium in Hemodialysis Patients: A New Understanding of the Old Problem

Sakaguchi Y.a · Hamano T.a · Isaka Y.b

Author affiliations

Departments of aComprehensive Kidney Disease Research and bNephrology, Osaka University Graduate School of Medicine, Suita, Japan

Related Articles for ""
Nakamoto H, et al. (eds): Recent Advances in Dialysis Therapy in Japan. Contrib Nephrol. Basel, Karger, 2018, vol 196, pp 58-63
https://doi.org/10.1159/000485700

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Chapter 1: New Opinions on Dialysis Therapy

Published online: July 24, 2018
Cover Date: 2018

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 0

ISBN: 978-3-318-06297-7 (Print)
eISBN: 978-3-318-06298-4 (Online)

Abstract

Background: Despite the prognostic significance of mineral and bone disorders in patients undergoing hemodialysis, very few studies have focused on magnesium metabolism in this population. Nephrologists have paid much attention to hypermagnesemia, which is sometimes caused by magnesium administration, but the clinical implication of low magnesium has been largely overlooked. Recently, several cohort studies have reported that lower serum magnesium levels are associated with an increased risk of all-cause and cardiovascular mortality among hemodialysis patients. In addition to its beneficial effect on endothelium, magnesium has been shown to inhibit the progression of vascular calcification both in vitro and in vivo. Although the exact underlying mechanism is still uncertain, magnesium can suppress the maturation of calciprotein particles, a candidate culprit for vascular calcification, which is promoted by high phosphate. Thus, magnesium seems to be useful to alleviate the phosphate-induced calcification stress. Consistently, the risk of cardiovascular death associated with hyperphosphatemia is attenuated among hemodialysis patients with high serum magnesium levels, whereas this risk is exacerbated among those with low serum magnesium levels. In the context of the bone-vascular axis, magnesium may also be involved in the risk of fracture. It should be noted that, although total serum magnesium levels of hemodialysis patients are often above the reference range, the concentration of ionized magnesium, a biologically active form of magnesium, is largely normal or even low. Summary: A growing number of observational studies have uncovered the relationship between lower serum magnesium levels and poorer survival of hemodialysis patients. Magnesium modulates the pathogenesis of mineral and bone disorders and might provide a novel therapeutic approach for vascular calcification. Key Messages: Future intervention studies should clarify whether magnesium supplementation and/or increasing dialysate magnesium concentration improves the prognosis of hemodialysis patients.

© 2018 S. Karger AG, Basel



Related Articles:

References

  1. de Baaij JH, Hoenderop JG, Bindels RJ: Magnesium in man: implications for health and disease. Physiol Rev 2015;95:1-46.
  2. Wyskida K, Witkowicz J, Chudek J, Więcek A: Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease. J Ren Nutr 2012;22:19-26.
  3. Luis D, Zlatkis K, Comenge B, García Z, Navarro JF, Lorenzo V, Carrero JJ: Dietary quality and adherence to dietary recommendations in patients undergoing hemodialysis. J Ren Nutr 2016;26:190-195.
  4. Brannan PG, Vergne-Marini P, Pak CY, Hull AR, Fordtran JS: Magnesium absorption in the human small intestine. Results in normal subjects, patients with chronic renal disease, and patients with absorptive hypercalciuria. J Clin Invest 1976;57:1412-1418.
  5. Nakashima A, Ohkido, Yokoyama K, Mafune A, Urashima M, Yokoo T: Proton pump inhibitor use and magnesium concentrations in hemodialysis patients: a cross-sectional study. PLoS One 2015:10:e0143656.
  6. Hess MW, de Baaij JH, Broekman MM, Bisseling TM, Haarhuis BJ, Tan AC, Te Morsche RH, Hoenderop JG, Bindels RJ, Drenth JP: Common single nucleotide polymorphisms in transient receptor potential melastatin type 6 increase the risk for proton pump inhibitor-induced hypomagnesemia: a case-control study. Pharmacogenet Genomics 2017;27:83-88.
  7. Sakaguchi Y, Hamano T, Kubota K, Oka T, Yamaguchi S, Matsumoto A, Hashimoto N, Mori D, Obi Y, Matsui I, Isaka Y: Anion gap as a determinant of ionized fraction of divalent cations in hemodialysis patients. Clin J Am Soc Nephrol DOI: 10.2215/CJN.07930717.
  8. Ter Braake AD, Shanahan CM, de Baaij JHF: Magnesium counteracts vascular calcification: passive interference or active modulation? Arterioscler Thromb Vasc Biol 2017;37:1431-1445.
  9. Sakaguchi Y, Hamano T, Isaka Y: Effects of magnesium on the phosphate toxicity in chronic kidney disease: time for intervention studies. Nutrients 2017;9:112.
  10. Diaz-Tocados JM, Peralta-Ramirez A, Rodríguez-Ortiz ME, Raya AI, Lopez I, Pineda C, Herencia C, Montes de Oca A, Vergara N, Steppan S, Pendon-Ruiz de Mier MV, Buendía P, Carmona A, Carracedo J, Alcalá-Díaz JF, Frazao J, Martínez-Moreno JM, Canalejo A, Felsenfeld A, Rodriguez M, Aguilera-Tejero E, Almadén Y, Muñoz-Castañeda JR: Dietary magnesium supplementation prevents and reverses vascular and soft tissue calcifications in uremic rats. Kidney Int 2017;92:1084-1099.
  11. Tzanakis IP, Stamataki EE, Papadaki AN, Giannakis N, Damianakis NE, Oreopoulos DG: Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study. Int Urol Nephrol 2014;46:2199-205.
  12. Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J, Jahnen-Dechent W: Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012;23:1744-1752.
  13. Keyzer CA, de Borst MH, van den Berg E, Jahnen-Dechent W, Arampatzis S, Farese S, Bergmann IP, Floege J, Navis G, Bakker SJ, van Goor H, Eisenberger U, Pasch A: Calcification propensity and survival among renal transplant recipients. J Am Soc Nephrol 2016;27:239-248.
  14. Bressendorff I, Hansen D, Schou M, Silver B, Pasch A, Bouchelouche P, Pedersen L, Rasmussen LM, Brandi L: Oral magnesium supplementation in chronic kidney disease stages 3 and 4: efficacy, safety, and effect on serum calcification propensity - a prospective randomized double-blinded placebo-controlled clinical trial. Kidney Int Rep 2016;2:380-389.
  15. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y: Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014;85:174-181.
  16. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Iseki K, Tsubakihara Y, Isaka Y; Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy: Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One 2014:9:e116273.
  17. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J: Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-3717.
  18. Kyriazis J, Kalogeropoulou K, Bilirakis L, Smirnioudis N, Pikounis V, Stamatiadis D, Liolia E: Dialysate magnesium level and blood pressure. Kidney Int 2004;66:1221-1231.
  19. Schmaderer C, Braunisch MC, Suttmann Y, Lorenz G, Pham D, Haller B, Angermann S, Matschkal J, Renders L, Baumann M, Braun JR, Heemann U, Küchle C: Reduced mortality in maintenance haemodialysis patients on high versus low dialysate magnesium: a pilot study. Nutrients 2017;9:926.
  20. Alfrey AC, Miller NL, Trow R: Effect of age and magnesium depletion on bone magnesium pools in rats. J Clin Invest 1974;54:1074-1081.
  21. Cunningham J, Rodríguez M, Messa P: Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J 2012:5(suppl 1):i39-i51.
  22. Sakaguchi Y, Hamano T, Wada A, Hoshino J, Masakane I: Magnesium and risk of hip fracture among patients undergoing hemodialysis. J Am Soc Nephrol DOI: 10.1681/ASN.2017080849.
  23. Rodríguez-Ortiz ME, Canalejo A, Herencia C, Martínez-Moreno JM, Peralta-Ramírez A, Perez-Martinez P, Navarro-González JF, Rodríguez M, Peter M, Gundlach K, Steppan S, Passlick-Deetjen J, Muñoz-Castañeda JR, Almaden Y: Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant 2014;29:282-289.
  24. Castiglioni S, Cazzaniga A, Albisetti W, Maier JA: Magnesium and osteoporosis: current state of knowledge and future research directions. Nutrients 2013;5:3022-3033.

Article / Publication Details

First-Page Preview
Abstract of Chapter 1: New Opinions on Dialysis Therapy

Published online: July 24, 2018
Cover Date: 2018

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 0

ISBN: 978-3-318-06297-7 (Print)
eISBN: 978-3-318-06298-4 (Online)

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

Table of Contents

Article

Recommend This
TOP